SureClick (Darbepoetin alfa) can improve perceived satisfaction and competence for anemia treatment and increase self-administration in non-dialyzed patients with chronic kidney disease
- Autores: Xavier Bonafont Pujol, Ramón Romero González, Isabel Martínez, M.D. del Pino, José M. Gil, Pedro Aranda Lara, Ramón Roca Tey, Joana Claverol, Mercedes Cucala
- Localización: Nefrología: publicación oficial de la Sociedad Española de Nefrología, ISSN 0211-6995, Vol. 33, Nº. 2, 2013, págs. 214-222
- Idioma: inglés
- Enlaces
-
Resumen
Background and aims:
SureClick ® is a prefilled pen for administration of darbepoetin alfa (DA) that is ready- to-use. We explored patient satisfaction with SureClick ® compared with prefilled syringes (PFS).
Methods:
Multicenter, prospective, 6-months, observational study in non-dialyzed patients with chronic kidney disease (CKD) treated with DA in PFS who switched to SureClick ® at baseline. Main outcomes were: change in Anemia Treatment Satisfaction Questionnaire (ATSQ-S), Perceived Competence for Anemia Scale (PCAS) and self- administration rate.
Results:
We enrolled 132 patients with a mean(SD) age of 71.3 (14.6) years, 57.6% women Mean(SD) ATSQ-S scores at baseline and final records were 25.5 (7.9) and 31.6 (4.9) (on a scale from 0 to 36 �maximum satisfaction-, mean change: 6.2, 95%CI: 4.6- 7.8, P <0.0001). The PCAS also increased significantly (4.3 (2.0) vs 5.6 (1.6), on a scale from 1 to 7 �maximum competence, P <0.0001). At baseline 47.7% of patients self-administered DA with PFS, vs 74.2% with SureClick ® ( P <0.001). No significant changes in hemoglobin were observed (11.4 (0.5) vs 11.6 (1.3) g/dl, P =0.193). Two patients (1.5%) had adverse reactions to SureClick ® (pain on application).
Conclusions:
Our results suggest that the change from PFS to SureClick ® could increase patient satisfaction and perceived competence in anemia management in non-dialyzed CKD patients, and could increase the self-administration rate, thereby reducing use of health resources
